US LNG exports surge but will buyers in China turn up?
Charles Mosseri Marlio, a ten percent owner of Nuvectis Pharma , Inc. (NASDAQ:NVCT), has recently purchased a significant amount of the company’s stock. According to a Form 4 filing with the Securities and Exchange Commission, Marlio executed two "P" transaction purchases totaling $269532. The company maintains strong financial health with a current ratio of 3.28, indicating solid liquidity to meet short-term obligations.
On June 17, 2025, Marlio acquired 5399 shares of Common Stock at a price of $8.11 per share. A subsequent purchase on June 18, 2025, involved 28043 shares within a price range of $7.91 to $8.11. The weighted average price for this second transaction was $8.05. InvestingPro analysis shows the stock has gained 78% over the past six months, with analyst price targets ranging from $15 to $25.
Following these transactions, the total shares owned by Emerald Hill Ventures SARL SPF., an entity which Marlio is the beneficial owner of, amounts to 2976203 shares. InvestingPro offers additional insights through its 10 exclusive ProTips for NVCT, helping investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.